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Abstract: Background: Although community-acquired pneumonia (CAP) severity assessment scores
are widely used, their validity in low- and middle-income countries (LMICs) is not well defined.
We aimed to investigate the validity and performance of the existing scores among adults in LMICs
(Africa and South Asia). Methods: Medline, Embase, Cochrane Central Register of Controlled
Trials, Scopus and Web of Science were searched to 21 May 2020. Studies evaluating a pneumonia
severity score/tool among adults in these countries were included. A bivariate random-effects
meta-analysis was performed to examine the scores’ performance in predicting mortality. Results:
Of 9900 records, 11 studies were eligible, covering 12 tools. Only CURB-65 (Confusion, Urea,
Respiratory Rate, Blood Pressure, Age ≥ 65 years) and CRB-65 (Confusion, Respiratory Rate, Blood
Pressure, Age ≥ 65 years) were included in the meta-analysis. Both scores were effective in predicting
mortality risk. Performance characteristics (with 95% Confidence Interval (CI)) at high (CURB-65 ≥ 3,
CRB-65 ≥ 3) and intermediate-risk (CURB-65 ≥ 2, CRB-65 ≥ 1) cut-offs were as follows: pooled
sensitivity, for CURB-65, 0.70 (95% CI = 0.25–0.94) and 0.96 (95% CI = 0.49–1.00), and for CRB-65,
0.09 (95% CI = 0.01–0.48) and 0.93 (95% CI = 0.50–0.99); pooled specificity, for CURB-65, 0.90 (95%
CI = 0.73–0.96) and 0.64 (95% CI = 0.45–0.79), and for CRB-65, 0.99 (95% CI = 0.95–1.00) and 0.43
(95% CI = 0.24–0.64). Conclusions: CURB-65 and CRB-65 appear to be valid for predicting mortality
in LMICs. CRB-65 may be employed where urea levels are unavailable. There is a lack of robust
evidence regarding other scores, including the Pneumonia Severity Index (PSI).
Keywords: community-acquired pneumonia; severity of illness index; developing countries; mortal-
ity; prognosis; systematic review; meta-analysis
1. Introduction
Community-acquired pneumonia (CAP) is considered the leading cause of global
deaths due to infectious diseases in all age groups, particularly in low- and middle-income
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countries (LMICs) [1]. Despite advances in pneumonia management and the development
of a pneumococcal conjugate vaccine, pneumonia remains a major cause of adult hospitali-
sation and mortality worldwide [2]. According to the Global Burden of Diseases, Injuries,
and Risk Factors Study 2016, more than 336 million episodes of lower respiratory tract
infections (LRTIs) were reported globally, corresponding to 65.9 million hospitalisations
and 2,377,697 deaths [3]. Reflecting the pneumococcal vaccination programme, death from
LRTIs in children under five years of age has declined between 2007 and 2017 by more
than 36%. Conversely, mortality in those aged 70 years and older has risen by 33.6% [4].
In sub-Saharan Africa, pneumonia accounts for approximately 4 million episodes and
200,000 deaths annually [2].
In high-income countries (HICs), the burden of CAP is high among the elderly, those
with chronic obstructive pulmonary disease, and individuals with multiple comorbidi-
ties [5]. In contrast, indoor air pollution, crowding, malnutrition and high HIV prevalence,
are considered the predominant risk factors in LMICs [6] and explain the higher disease
burden amongst young and middle-aged adults in LMICs compared to HICs [2,7].
Several risk predictive scores/tools, such as Pneumonia Severity Index (PSI) and
CURB-65, have been developed to facilitate site-of-care decision making, including predict-
ing mortality, hospital admission need, and treatment intensity [8]. PSI [9], which consists
of 20 variables including laboratory tests, places patients into five categories (I–V) for mor-
tality, whereas CURB-65 [10] classifies patients into low-, intermediate- or high-risk groups
based on five variables: confusion, urea, respiratory rate, blood pressure and age. Such
scores support clinical judgement and aid the rationalisation of management decisions
through patient risk categorisation [8]. This has been shown to improve the accuracy of
triage to determine whether patients can be safely treated at home or require hospital
admission, as well as support the appropriate selection of antimicrobial agents [11].
The use of severity assessment scores is of particular value in CAP management in
LMICs, given its high prevalence coupled with growing rates of antimicrobial resistance (AMR)
and limited or lack of access to laboratory, radiological diagnostics or advanced care settings
such as intensive care units (ICU) [12]. Although widely used [6], the performance, validity
and reliability of CAP scoring tools developed in HICs [8] are not well defined in LMICs.
Such tools may be less suitable for use in LMICs since they have been derived from a HIC
population with different population characteristics, such as age and ethnicity, comorbidity
(including coinfection with HIV), nutritional status and tuberculosis prevalence/clinical
overlap [13–16]. To date, we believe there has not been a comprehensive evaluation of the
validity of CAP scoring tools in LMIC populations, despite some evidence showing their
poor performance [8,17,18]. CRB-65 performed poorly in a Malawian hospital, where it was
insensitive to predicting mortality compared to a locally developed score [19]. Furthermore,
the inconsistent results arising from implementing these tools in LMICs, we believe, support
the need for a systematic evaluation of their validity in these specific populations [2].
Herein, we systematically investigated the association between the various severity
assessment scores and patient outcomes and subsequently evaluated their validity and
predictive performance in adults with CAP in LMICs, particularly in Africa and South
Asia. This will facilitate future guidance on their utility in LMICs and consideration of
whether existing scoring tools need to be adapted for use in LMICs.
2. Materials and Methods
This systematic review and meta-analysis was performed in accordance with the
PRISMA statement [20]. The protocol was registered with PROSPERO, CRD42020182620.
2.1. Search Strategy and Data Sources
Five electronic databases were systematically searched from inception up to 21 May,
2020. These included Medline (via Ovid), Embase (via Ovid), Cochrane Central Register
of Controlled Trials, Scopus and Web of Science. Key terms and their synonyms were
used for three concepts: CAP patients, severity assessment scores and low- and middle-
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income countries. The following combinations of search terms were used for Scopus:
((“Community-acquired pneumonia” OR “Bronchopneumoni*” OR “Pneumoni*” OR “Acute
respiratory infection*” OR “acute respiratory illness” OR “lower respiratory tract infection*” OR
“lower respiratory infection*”) AND (“low-middle-income countr*” OR “LMIC*” OR “low-income
countr*” OR “less developed countr*” OR “middle-income countr*” OR “Malawi” OR “Kenya”
OR “Tanzania” OR “Africa” OR “South Africa” OR “Developing countr*”) AND (“Prognos*”
OR “Score*” OR “Tool*” OR “severity assessment” OR “risk assessment” OR “Predict*” OR
“Mortality score*” OR “Severity score*” OR “PSI” OR “CURB-65” OR “CURB65” OR “CRB65”
OR “CRB-65” OR “SOAR” OR “SCAP” OR “PIRO” OR “RISC” OR “mRISC” OR “Pneumonia
severity index” OR “I-DROP”)). The search was limited to English language, with no
additional restrictions. The search strategies were reviewed by two co-authors (NA, AK)
and an expert academic librarian. The reference lists of relevant articles were screened
in addition to supplementary, non-systematic hand-searching. The OpenGrey database




We included studies of any design (randomised control trials or observational studies)
that involved adults with CAP and examined pneumonia severity scores performance
to predict mortality, hospitalisation, ICU admission, mechanical ventilation or treatment
intensity. Additionally, the included studies were undertaken in LMICs, in Africa or
South Asia, as they represent the majority of the countries in the LMICs list by 46% and
12%, respectively, according to the World Bank classification [21]. These countries also
account for the highest mortality secondary to LRTIs, including pneumonia [3]; there, it is
crucial to improve the appropriate use of antimicrobials due to rising rates of antimicrobial
resistance [22]. Qualitative studies, abstracts, reports, commentaries, editorials and book
chapters were excluded. We also excluded studies that included patients with other types
of pneumonia, such as hospital-acquired, healthcare-associated, ventilator-associated or
aspiration pneumonia, or if a single prognostic factor or other biomarkers were used
instead of the clinical scores.
2.2.2. Screening
All identified records were imported into Covidence® (www.covidence.org), accessed
on 25 May 2020, where duplicate citations were removed. Titles and abstracts, followed by
full-text screenings, were performed by the principal author (SA). Co-authors (NA, AA)
independently validated the selection by screening a randomly selected sample of 20% at
each stage.
2.3. Data Extraction and Quality Assessment
Data were extracted into Excel spreadsheets by the principal author (SA), including
study characteristics (first author, year, country, study design, setting, population char-
acteristics and sample size), severity score, CAP definition, study outcomes, including
mortality, ICU admission, hospitalisation, treatment intensity, mechanical ventilation need
and time to clinical stability and, if possible, true positive (TP), false positive (FP), false
negative (FN), and true negative (TN) values. These values were tabulated for patients
with high-risk (CURB-65 ≥ 3 and CRB-65 ≥ 3) and intermediate-risk (CURB-65 ≥ 2 and
CRB-65 ≥ 1) cut-offs. Methodological quality of the studies was assessed using Quality in
Prognosis Studies (QUIPS) criteria [23], a tool recommended by the Cochrane Prognosis
Methods Group [24]. This tool consists of six domains, where each has a score from 0 to 2.
As used by Marti et al. [25], studies with an overall score between 11 and 12, 9 and 10, or 8
or less were considered of low-, moderate-, or high-risk of bias, respectively. Independently,
co-authors (NA, AA) validated the extraction and quality assessment of a 20% randomly
Healthcare 2021, 9, 1202 4 of 17
selected sample. For any disagreement, author (AK) was involved until consensus was
achieved.
2.4. Data Analysis
When at least four studies (a minimum number required to use MIDAS [26] command)
were available for each scoring tool and outcome, the performance of the identified tools
was assessed in two ways: firstly, the association between different severity scores at the
studied cut-offs and the reported event (mortality) was examined using pooled relative
risks (RRs). Furthermore, a bivariate model was used to calculate the scores’ performance
characteristics, including the pooled sensitivity, specificity, positive likelihood ratios (PLRs),
negative likelihood ratios (NLRs) and diagnostic odds ratios (DORs). Area under the re-
ceiver operating characteristic (AUROC) curve was obtained to evaluate the overall scores’
accuracy. The results were described as point estimates and 95% confidence intervals.
Heterogeneity was tested using I2 index, where a value of <25%, 25–50%, and >50% indi-
cated low, moderate, and high heterogeneity, respectively [27]. Data were combined using
the random-effects model when I2 > 50%. When meta-analysis could not be conducted
due to the nature of the available data or the small number of studies, the results were
narratively summarised. Publication bias was explored using Deeks’ funnel plot [28],
where a p-value < 0.05 indicated the presence of bias. All analyses were carried out in
STATA IC 16.1 (Stata Corp, College Station, TX, USA), where the MIDAS [26], which can
be applied only to data from a minimum of four studies, and metan commands were used.
3. Results
3.1. Search Results
Titles and abstracts of 9900 records were screened against the inclusion criteria after
deduplication; however, only 31 studies were considered for full-text screening. Of these,
11 studies fulfilled the eligibility criteria; however, only 6 studies that examined CURB-65
and CRB-65 included sufficient data and were included in the final meta-analysis [19,29–33].
The study selection is summarised in Figure 1.
3.2. Study Characteristics
The eligible 11 studies were published between 2008 and 2019, with a total of 3740
patients from 7 LMICs. Eight studies were conducted in Africa (Malawi [18,19,34], Nige-
ria [30], South Africa [29,33], Uganda [17] and Egypt [35]), and three were from South
Asia (Pakistan [32] and India [31,36]). The average age of the patients ranged from 34 to
69.9 years, and male percentage varied between 38.6% and 62.1%. The reported mortality
rate ranged from 2–40%. Most of identified studies assessed patients in medical wards,
emergency departments or outpatient settings. Only one study exclusively evaluated
elderly patients (≥60 years) admitted to ICU [35]. A total of 12 scores, CURB-65 [30–35],
CRB-65 [19,29,30,32–34], PSI [31,36], SWAT-Bp [18,19,34], CURB-45 [33], SCAP [35], ADL
score [35], modified IDSA/ATS criteria [34], Koss et al. tool [17], CTA [33], ACHU [33]
and SMRT-CO [34], were examined in these 11 studies, 7 of which reviewed the per-
formance of more than one score [19,30–35]. All studies addressed mortality as either in-
hospital [18,19,33], 30-day [17,30,32,34,35], in-hospital or within 30 days of discharge [31,36]
or in-hospital or within 14 days following emergency department visit for those discharged
earlier [29]. Four studies included other outcomes (ICU admission [30,31], mechanical venti-
lation [35], hospitalisation and time to clinical stability [29]). Table 1 summarises the studies
characteristics (additional characteristics in the Supplementary Materials (Table S1)).
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3.3. Methodological Quality
Studies of any quality were included in the meta-analysis. Risk of bias was considered
low in five studies (score ≥ 11), moderate in four studies (score 9–10), and high in two
studies (score ≤ 8). Quality assessment is described in the Supplementary Materials
(Table S2).
3.4. Study Outcome
Although 12 severity scores were initially identified (scores’ components are provided
in the Supplementary Materials Table S3), only two of them (CURB-65, CRB-65) were
examined in four studies or more. In addition, only a few studies assessed outcomes other
than mortality. Such scores and outcomes were excluded from the meta-analysis, with their
findings reported narratively in the Supplementary Materials (Table S4). Consequently, out
of the scores identified, the meta-analysis was only performed on CURB-65 and CRB-65 in
predicting mortality.
3.5. Analysis of the Outcome
3.5.1. Association between CURB-65/CRB-65 and Mortality
All studies included in the meta-analysis (four for CURB-65 and five for CRB-65)
showed that the high-risk class (CURB-65 ≥ 3, CRB-65 ≥ 3) was associated with increased
mortality, with pooled RRs of 9.16 (3.61–23.25) and 6.67 (3.19–13.95) for CURB-65 and
CRB-65, respectively. The intermediate-risk class (CURB-65 ≥ 2, CRB-65 ≥ 1) was also
related to high mortality risk, with pooled RRs of 9.90 (1.63–60.09) and 3.55 (1.31–9.66) for
CURB-65 and CRB-65, respectively. Due to the significant heterogeneity, the random-effects
model was used (Figure 2).
3.5.2. CURB-65 Predictive Performance for Mortality
From the eligible 11 studies, CURB-65 was assessed in 6 studies; however, 2 were
excluded due to lack of data necessary to obtain the performance characteristics. Only four
studies were finally analysed, with a total of 1378 patients. Two of these studies excluded
HIV patients. The score performance characteristics are presented in Table 2. High-risk cut-
off (≥3) showed better specificity, PLR, and AUROC of 0.90 (95% CI 0.73–0.96), 6.72 (95% CI
3.84–11.76) and 0.90 (95% CI 0.87–0.93), respectively. On the other hand, intermediate-risk
cut-off (≥2) had an improved sensitivity and NLR of 0.96 (95% CI 0.49–1.00) and 0.06
(95% CI 0.00–1.12), respectively. Forest plots of the performance characteristics and the
receiver operating characteristic curves are presented in Figures 3–5 and the Supplementary
Materials Figure S1.
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Table 1. Characteristics of the included studies.
Author.
(Year) Country Study Settings Study Design Age in Years
Male
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Prospective
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Table 1. Cont.
Author.
(Year) Country Study Settings Study Design Age in Years
Male

























































60.4 (±18.5) 65 (47.7) 137 CURB-65 andCRB-65 Mortality
30-day
mortality 13.1
Age data are expressed in either median (range/interquartile range (IQR)) or mean ± standard deviation (SD); NR: Not reported; n: number of patients; MV: mechanical ventilation; ICU: intensive care unit; ED:
emergency department; IQR: interquartile range; SCAP: severe community-acquired pneumonia; ADL: activities of daily living score; CURB-65: confusion, urea, respiratory rate, blood pressure, age ≥ 65;
CRB-65: confusion, respiratory rate, blood pressure, and age ≥ 65; SMRT-CO: systolic blood pressure, multilobe infiltrate, respiratory rate, tachycardia, confusion, oxygen; SWAT-Bp: sex, muscle wasting,
non-ambulatory, temperature, and blood pressure; IDSA/ATS: Infectious Diseases Society of America/American Thoracic Society; CTA: classification tree analysis; ACHU: Age, Confusion, HIV, Urea; PSI:
Pneumonia Severity Index. a IQR; b only 439 patients were assessed for 30-day mortality.
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Table 2. Pooled performance characteristics of CURB-65 and CRB-65 for predicting mortality in high- and intermediate-risk
cut-offs in community-acquired pneumonia patients.
High-Risk Cut-Offs Intermediate-Risk Cut-Offs
CURB-65 ≥ 3 CRB-65 ≥ 3 CURB-65 ≥ 2 CRB-65 ≥ 1
Pooled Estimate Summary Statistic Summary Statistic Summary Statistic Summary Statistic
Sensitivity (95% CI) 0.70 (0.25–0.94) 0.09 (0.01–0.48) 0.96 (0.49–1.00) 0.93 (0.50–0.99)
Specificity (95% CI) 0.90 (0.73–0.96) 0.99 (0.95–1.00) 0.64 (0.45–0.79) 0.43 (0.24–0.64)
PLR (95% CI) 6.72 (3.84–11.76) 8.65 (2.70–27.66) 2.65 (1.77–3.98) 1.64 (1.19–2.26)
NLR (95% CI) 0.33 (0.09–1.17) 0.92 (0.77–1.11) 0.06 (0.00–1.12) 0.15 (0.02–1.47)
DOR (95% CI) 20.19 (7.32–55.63) 9.36 (2.57–34.03) 41.02 (2.87–586.97) 10.70 (1.04–109.87)
AUROC (95% CI) 0.90 (0.87–0.93) 0.91 (0.88–0.93) 0.81 (0.77–0.84) 0.70 (0.66–0.74)
CI: Confidence interval; PLR: positive likelihood ratio; NLR: negative likelihood ratio; DOR: diagnostic odds ratio; AUROC: area under the
receiver operating characteristic curve; CURB-65, confusion, urea, respiratory rate, blood pressure, age ≥ 65 years; CRB-65, confusion,
respiratory rate, blood pressure, age ≥ 65 years.
3.5.3. CRB-65 Predictive Performance for Mortality
Similarly, of the 11 studies, 6 studies examined CRB-65 performance. However,
only five studies included sufficient data on performance and were eligible for analysis,
involving a total of 1941 patients. HIV patients were excluded from one of the analysed
studies. Similar to CURB-65, CRB-65 high-risk cut-off (≥3) showed higher specificity,
PLR, and AUROC of 0.99 (95% CI 0.95–1.00), 8.65 (95% CI 2.70–27.66), and 0.91 (95% CI
0.88–0.93), respectively. In contrast, higher sensitivity and better NLR of 0.93 (95% CI
0.50–0.99) and 0.15 (95% CI 0.02–1.47), respectively, were seen with the intermediate-risk
cut-off (≥1). Pooled performance characteristics for each studied cut-off are summarised
in Table 2. Forest plots and the receiver operating characteristic curves are available in
Figures 3–5 and the Supplementary Materials Figure S1.
3.6. Publication Bias
The presence of publication bias was assessed by Deeks’ funnel plot (the Supple-
mentary Materials Figure S2). The funnel plots for CURB-65 and CRB-65 at high-risk
cut-offs did not show any evidence of bias (p = 0.18 and 0.48, respectively). However,
the plots’ shape at their intermediate-risk cut-offs revealed asymmetry (p = 0.04 and 0.03,
respectively).
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similar conclusion [37]. Both meta-analyses [8,37], though, included only a single LMIC
study conducted in Pakistan [32], which was also included in our meta-analysis.
According to our AUROC findings, intermediate- and high-risk scores’ cut-offs dis-
played excellent accuracy for CURB-65 (0.81 and 0.90, respectively) and acceptable to
outstanding accuracy for CRB-65 (0.70 to 0.91, respectively) in predicting mortality among
patients with CAP [38]. At high-risk cut-off (≥3), no substantial difference was observed
between the scores’ performance, with AUROC greater than those reported by Ebell et al.,
who examined the discrimination of CRB-65 by analysing 29 studies, excluding studies
from low-income and lower-middle-income countries, and Chalmers et al., whereas CRB-
65 at intermediate-risk cut-off (≥1) had the lowest AUROC [8,39]. These differences may
be attributed to the variations in population characteristics, particularly patient age and
comorbidities.
Our analysis also revealed differences in the performance characteristics among the
assessed scores (CURB-65, CRB-65). Both scores appear to have improved specificity at
their high-risk cut-offs (CURB ≥ 3, CRB-65 ≥ 3), suggesting that they correctly identify
patients who are not at increased risk of mortality. However, the relatively poor sensitivity,
particularly for CRB-65, may lead to misclassifications and poor management of possibly
high-risk patients, which may limit their utility in clinical practice and decision making in
LMICs. Contrastingly, better sensitivity and lower specificity are seen at their intermediate-
risk cut-offs (CURB-65 ≥ 2, CRB-65 ≥ 1). In terms of likelihood ratios, CURB-65 and
CRB-65 showed better PLRs at their high-risk cut-offs, with superiority for the latter (6.72
vs. 8.65), suggesting that CRB-65 performs better in this aspect, although a PLR of greater
than 10 is essential [40]. Both scores at the studied cut-offs yielded NLRs of less than one;
however, based on previous findings, only CURB-65 (≥2) had a robust result of less than
0.1 [40].
According to our results, it seems likely that both scoring systems could be used in
LMICs for mortality prediction, as they both support appropriate management approaches.
Overall, high-risk cut-offs are useful to allocate high-mortality-risk patients to a higher level
of care unit, such as high-dependency units in HICs, where beds are available. However, in
facilities where such units and resources are not accessible, these cut-offs may be employed
to support other management decisions such as intravenous administration of antibiotics,
if available. Intermediate-risk cut-offs might be a more practical and valuable option to
guide hospitalisation for patients in LMICs, as this would reduce the risk of increased
mortality among individuals with CAP.
Investigating other scores performance and outcomes in LMICs was not possible.
The well-known and validated PSI tool has not yet been extensively studied in LMICs.
PSI implementation also requires multiple clinical and laboratory variables [9], which are
typically impractical to obtain in resource-scarce areas, especially if patients are charged
for tests. Newer assessment tools, such as SWAT-Bp and SCAP, have been assessed in a
very few studies in LMICs, and some have shown good discrimination ability. However,
despite these promising results, the lack of evidence evaluating these scores limits their
generalisability, and further studies are required to validate and establish their role among
such populations. Marti and colleagues assessed several severity scores to predict early
mortality (<14 days), ICU admission and treatment intensity, and found that newer scores,
such as ATS/IDSA 2007 minor criteria, SCAP and SMART-COP, performed better compared
to the classical tools (PSI, CURB-65) [25]. However, again, all but one study was conducted
in HICs, and the majority addressed ICU admission as their outcome.
Our findings identified gaps in the existing literature warranting future research. The
main issue is the small number of studies evaluating severity scores in LMICs. As a result,
it was not possible to study most of the identified scores’ validity, particularly the newly
developed and refined ones. It was also impractical to examine their use in predicting other
important outcomes as we initially planned in our published study protocol (PROSPERO
protocol, CRD42020182620), such as ICU admission, hospitalisation and treatment intensity,
since all of the eligible studies only evaluated mortality as the main outcome. This was
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disappointing; however, this itself highlights the gap in the available evidence for using
these tools for their intended purpose and emphasises the need for future research to see
how these tools can be utilised to assess other outcomes. Due to the limited resources
available in LMICs, attempts to develop strategies to improve CRB-65 (≥3) sensitivity,
which does not require any laboratory results, are encouraged. Of note, our analyses
were limited to adult populations; the performance of these prognostic scoring systems in
paediatric patients in LMICs was not assessed in this report.
We are aware that our study has some potential limitations. We initially excluded
a large number of studies, which could be explained by the fact that the search terms
were wide and searched both as subject headings and free-text terms to ensure a complete
and comprehensive search strategy. Another significant limitation is the substantial hetero-
geneity amongst the studies, which may have affected the results. However, high levels
of heterogeneity are often seen in diagnostic test accuracy reviews [41]. In addition to
the considerable variability in the patients’ eligibility criteria, study designs and settings,
differences were found in mortality definition and pneumonia diagnostic criteria between
studies. This is possibly due to the limited resources available in such settings as well as
the lack of reliable and timely patients’ records, which in turn could result in the inclusion
of misdiagnosed patients and patients with alternative LRTIs. Furthermore, HIV-infected
patients were excluded from several studies included in our systematic review and meta-
analysis, which may not represent the actual population demographics, considering the
high prevalence of HIV especially in sub-Saharan African countries. Additional analyses
stratified based on these differences were not possible to conduct due to the limited studies
identified, which may have affected the findings of our work. Moreover, most of the
included studies failed to provide details about management approaches, such as antibiotic
treatment regimens and any oxygen, fluids, electrolytes or cardiovascular support needed,
which may have influenced patient outcomes. Lastly, although changing the cut-off point
from four to three analysed studies was unlikely to affect our results since none of the
other scores were examined in three eligible studies, changing the cut-off to two studies
would have allowed us to evaluate additional scores, namely, PSI and SWAT-Bp, as they
were examined in two studies. However, obtaining pooled estimates for performance
characteristics (sensitivity, specificity) requires at least four studies as recommended by
MIDAS command in STATA [26].
5. Conclusions
Despite the differences in the scores’ performance characteristics, we found that CURB-
65 and CRB-65 appear to be valid prognostic scoring systems for predicting death among
adults with CAP in LMICs. Although CURB-65 exhibited a stronger association with
mortality prediction and better performance in many aspects, this review suggests that the
simple and readily available CRB-65 is also an appropriate score to employ where limited
access to laboratory tests means that urea levels are unavailable. Given the differences in
population characteristics and the limited resources available, further research is needed to
address other important outcomes and to develop, adjust and validate other scores that are
easier to use in such settings. We will be following such developments in the future.
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